OBJECTIVE: To investigate platelet activation and deposition in human saphenous vein and internal mammary artery grafts following coronary artery bypass in vitro and in vivo, as well as inhibition of activation by the platelet selective nitric oxide donor S-nitrosoglutathione (GSNO). DESIGN: Controlled in vitro and in vivo studies. SETTING: Tertiary cardiac centre. PATIENTS: 24 patients undergoing coronary artery bypass surgery requiring vein and artery grafts. INTERVENTIONS: In vitro: human platelet rich plasma was perfused through segments of vein and artery, with or without GSNO 10(-6) M, and the platelet count was measured in the effluent. In vivo: indium-111 labelled antibody against the platelet alpha granule protein GMP-140 was injected at the end of coronary bypass grafting and gamma counts were compared between vein and artery grafts with or without systemic infusion of GSNO (40 nmol/min). RESULTS: In vitro: platelet count in perfused vein (< 70% of baseline) decreased more than in artery segments (89-94% of baseline) (p < 0.001). The platelet count was unchanged with GSNO in vein and artery segments. In vivo: gamma counts were greater at all time points over vein than artery grafts (p < 0.05), and were reduced by infusion of GSNO (p < 0.05). CONCLUSIONS: Platelet activation is greater in vein than in artery grafts in vitro and in vivo. Activation, which contributes to early vein graft failure, was inhibited by GSNO.
OBJECTIVE: To investigate platelet activation and deposition in human saphenous vein and internal mammary artery grafts following coronary artery bypass in vitro and in vivo, as well as inhibition of activation by the platelet selective nitric oxidedonorS-nitrosoglutathione (GSNO). DESIGN: Controlled in vitro and in vivo studies. SETTING: Tertiary cardiac centre. PATIENTS: 24 patients undergoing coronary artery bypass surgery requiring vein and artery grafts. INTERVENTIONS: In vitro: human platelet rich plasma was perfused through segments of vein and artery, with or without GSNO 10(-6) M, and the platelet count was measured in the effluent. In vivo: indium-111 labelled antibody against the platelet alpha granule protein GMP-140 was injected at the end of coronary bypass grafting and gamma counts were compared between vein and artery grafts with or without systemic infusion of GSNO (40 nmol/min). RESULTS: In vitro: platelet count in perfused vein (< 70% of baseline) decreased more than in artery segments (89-94% of baseline) (p < 0.001). The platelet count was unchanged with GSNO in vein and artery segments. In vivo: gamma counts were greater at all time points over vein than artery grafts (p < 0.05), and were reduced by infusion of GSNO (p < 0.05). CONCLUSIONS: Platelet activation is greater in vein than in artery grafts in vitro and in vivo. Activation, which contributes to early vein graft failure, was inhibited by GSNO.
Authors: S Goldman; J Copeland; T Moritz; W Henderson; K Zadina; T Ovitt; J Doherty; R Read; E Chesler; Y Sako Journal: Circulation Date: 1989-11 Impact factor: 29.690
Authors: T M Palabrica; B C Furie; M A Konstam; M J Aronovitz; R Connolly; B A Brockway; K L Ramberg; B Furie Journal: Proc Natl Acad Sci U S A Date: 1989-02 Impact factor: 11.205
Authors: Z H Yang; D Diederich; K Schneider; R Siebenmann; P Stulz; L von Segesser; M Turina; F R Bühler; T F Lüscher Journal: Circulation Date: 1989-10 Impact factor: 29.690
Authors: Nadzeya V Marozkina; Sean Yemen; Molly Borowitz; Lei Liu; Melissa Plapp; Fei Sun; Rafique Islam; Petra Erdmann-Gilmore; R Reid Townsend; Cheryl F Lichti; Sneha Mantri; Phillip W Clapp; Scott H Randell; Benjamin Gaston; Khalequz Zaman Journal: Proc Natl Acad Sci U S A Date: 2010-06-08 Impact factor: 11.205
Authors: Amrita Ahluwalia; Paul Foster; Ramona S Scotland; Peter G McLean; Anthony Mathur; Mauro Perretti; Salvador Moncada; Adrian J Hobbs Journal: Proc Natl Acad Sci U S A Date: 2004-01-23 Impact factor: 11.205